Stenocare AS (OCSE:STENO) Other Stockholders Equity: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:STENO Stenocare AS OCSE:STENO
48 GF Score
Price kr1.01
GF Value kr2.31
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Stenocare AS Other Stockholders Equity?

Stenocare AS OCSE:STENO +3.06% 48 Other Stockholders Equity is kr0.00 Mil as of Mar. 2026. GuruFocus rates OCSE:STENO with a GF Score™ of 48/100 and a GF Value™ of kr2.31 (Possible Value Trap). The stock has 4 warning signs investors should review.

Stenocare AS's Other Stockholders Equity for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Stenocare AS's quarterly Other Stockholders Equity increased from Sep. 2025 (kr0.00 Mil) to Dec. 2025 (kr0.09 Mil) but then declined from Dec. 2025 (kr0.09 Mil) to Mar. 2026 (kr0.00 Mil).

Stenocare AS's annual Other Stockholders Equity stayed the same from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr0.00 Mil) but then increased from Dec. 2024 (kr0.00 Mil) to Dec. 2025 (kr0.09 Mil).

Stenocare AS Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Stenocare AS's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stenocare AS Other Stockholders Equity Chart

Stenocare AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.09

Stenocare AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.09 0.00
OCSE:STENO
48GF Score
Stenocare AS OCSE:STENO
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stenocare AS Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of kr0.00 Mil mean?
Stenocare AS (OCSE:STENO) has a Other Stockholders Equity of kr0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Stenocare AS and its competitors.
Is Stenocare AS's Other Stockholders Equity too high?
Stenocare AS's current Other Stockholders Equity is kr0.00 Mil. Overall, Stenocare AS has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Other Stockholders Equity compare to ZTS and UTHR?
Stenocare AS's Other Stockholders Equity of kr0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Stenocare AS and its competitors. Stenocare AS's current Other Stockholders Equity is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (OCSE:STENO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.31, compared to a current price of kr1.01 — trading 56.3% below its estimated fair value. The current Other Stockholders Equity is kr0.00 Mil. Stenocare AS's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Stenocare AS (OCSE:STENO), the current Other Stockholders Equity is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stenocare AS (OCSE:STENO) Overvalued in 2026?

Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued. The current stock price of kr1.01 is trading 56.3% below its estimated GF Value™ of kr2.31. GuruFocus considers Stenocare AS to be Possible Value Trap.

Key valuation signals for OCSE:STENO:

  • Other Stockholders Equity: kr0.00 Mil
  • GF Value™: kr2.31 vs. price of kr1.01 (56.3% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the OCSE:STENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stenocare AS Business Description

Other Exchanges S7C:Germany
Address Lejrvej 9, Vaerlose, DNK, 93500
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
48GF Score

Get the complete analysis for OCSE:STENO

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.01
Price
kr2.31
GF Value